CJC-1295 DAC: Albumin-Binding GHRH Analogue Research Guide (2026)
Last updated
Introduction (research-only scope)
CJC-1295 DAC is the albumin-binding form of the GHRH(1-29) analogue: the same peptide backbone as CJC-1295, plus a chemical group that lets it attach to circulating albumin and stay in the bloodstream for days rather than minutes. This guide explains that difference, what the published studies actually tested, and how to verify research-grade material.
Research use only. The material described here is a laboratory reagent for in-vitro research by qualified professionals. It is not a medicine, supplement, cosmetic ingredient or veterinary product, is not for human or animal use, and nothing on this page is medical advice or a claim of effect in any person.
What is CJC-1295 DAC?
CJC-1295 DAC (molecular mass 3775.4, same CAS family 863288-34-0) carries a maleimidopropionic acid group at the C-terminus that forms a covalent bond with cysteine-34 of serum albumin. The non-DAC form, catalogued separately as CJC-1295 (mass 3367.9), lacks that group. Our comparison CJC-1295 vs CJC-1295 DAC sets them side by side; the mass difference is the quickest way to tell which material you actually have.
How the reported mechanism works
GHRH receptor agonism
Once bound to albumin, the conjugate still activates the GRF receptor on the anterior pituitary, which the 2005 Endocrinology study demonstrated in rats using hGRF(1-29)-albumin bioconjugates.
What the drug affinity complex changes
The DAC does not change which receptor is engaged; it changes exposure over time. That is why the two forms answer different experimental questions: pulsatile stimulation versus sustained elevation, a distinction that matters in any model where the pattern of receptor activation is part of the biology.
What the published evidence covers
The 2006 clinical pharmacology study in healthy adults, which reported prolonged elevation of growth hormone and IGF-I, used this DAC form. Development stopped short of an approved product. For laboratory work the useful pairing is DAC with non-DAC in the same design, since the peptide sequence is constant and only the exposure profile differs.
How to verify a CJC-1295 DAC research peptide is real and pure
Two tests answer two different questions: mass spectrometry confirms identity (expected molecular mass 3775.4), HPLC quantifies purity. Our specification is at least 98%. Check the batch number printed on your vial against the lab reports archive: where a batch has been tested, its report is published there and links to the testing laboratory’s own verification page. If your batch is not listed yet, ask us for its documentation before use; a “typical” certificate is not evidence for a specific vial. See how to read a certificate of analysis.
Storage and reconstitution
Store the lyophilised material sealed, dry and protected from light at 2 to 8 °C for routine laboratory use, colder for long-term archiving. After reconstitution with bacteriostatic water, keep refrigerated and use within the window your protocol defines; repeated freeze-thaw cycles degrade peptides. General handling for all our reagents is in the peptide storage protocol.
Regulatory status
CJC-1295 DAC is not an authorised medicine in the European Union, the United Kingdom or the United States. It is named on the WADA Prohibited List (section S2, growth hormone releasing factors, among the GHRH analogues), prohibited at all times; the live list is the binding reference. Research-grade material supplied here is not a medicine and is for in-vitro laboratory use only. The wider framework, including anti-doping status, is described in the peptide risk profile.
Why labs choose our CJC-1295 DAC
Batch-numbered vials, published reports where a batch has been tested, shipping from an EU warehouse with tracking (no customs inside the EU) and prices shown with VAT included. Product page: CJC-1295 DAC 5 mg. Country-by-country sourcing questions are covered in the buyer guide Buy CJC-1295 DAC in Europe.
References
- Jette L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005. PubMed 15817669
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683